[{"id":"06161865-7dd7-428b-8b07-203a605930d9","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=e0c7cb58d688423eb5b1993afb3cdcff","created_at":"2026-06-27T01:56:55.873Z","updated_at":"2026-06-27T01:56:55.873Z","phase":"Phase 1","brief_title":"A Phase I clinical trial evaluating GLB-001 for the treatment of myeloid malignancies","source_id_and_acronym":"CTR20240931","lead_sponsor":"Hangzhou Gebo Biomedical Co., Ltd.","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 05/30/2024","start_date":" 05/30/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"2e93fafb-a232-444f-af49-b9b004cc9d9a","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=a07461e6a98e4957a30050298fdb014b","created_at":"2026-06-27T02:17:04.000Z","updated_at":"2026-06-27T02:17:04.000Z","phase":"Phase 2","brief_title":"Phase II clinical trial of FCN-338 in combination with azacitidine or chemotherapy for the treatment of myeloid neoplasms.","source_id_and_acronym":"CTR20231176","lead_sponsor":"Chongqing Fuchuang Pharmaceutical Research Co., Ltd.","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • FCN-338"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/07/2023","start_date":" 08/07/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"c9b95c96-83f4-48d7-ad93-c49c6f3d13a0","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=db5cf3940b5149e699042c6ea111e955","created_at":"2026-06-27T02:11:38.113Z","updated_at":"2026-06-27T02:11:38.113Z","phase":"Phase 3","brief_title":"A Phase III clinical trial of XY0206 tablets in patients with relapsed/refractory acute myeloid leukemia with FLT3-ITD mutations.","source_id_and_acronym":"CTR20231024","lead_sponsor":"Shijiazhuang Yiling Pharmaceutical Co., Ltd.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • mitoxantrone • fludarabine IV • XY0206"],"overall_status":"Recruiting","enrollment":" Enrollment 312","initiation":"Initiation: 07/26/2023","start_date":" 07/26/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"266ae433-cacc-4f47-a3b5-a22919a6a949","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=ef6246c452564f48be2cf4523d1cb1d6","created_at":"2026-06-27T02:36:03.512Z","updated_at":"2026-06-27T02:36:03.512Z","phase":"Phase 1","brief_title":"A multicenter, open-label phase Ib/II clinical trial investigating the efficacy and safety of 6MW3211 injection as monotherapy or in combination with azacitidine or azacitidine and veneclade in patients with acute myeloid leukemia or myelodysplastic syndrome.","source_id_and_acronym":"CTR20221156","lead_sponsor":"Maiwei (Shanghai) Biotechnology Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • safimestomig (6MW3211)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"3b1cedd4-b9f7-4603-b8e2-65416b68e452","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=09ef1ec07ce94d33b2eb6e1767e8d042","created_at":"2026-06-27T02:46:11.340Z","updated_at":"2026-06-27T02:46:11.340Z","phase":"Phase 1","brief_title":"A Phase I clinical study evaluating the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of LH-1802 capsules.","source_id_and_acronym":"CTR20222026","lead_sponsor":"Jiangsu Lianhuan Pharmaceutical Co., Ltd.","biomarkers":" FLT3 • BCL2","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 01/11/2023","start_date":" 01/11/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"9a700c20-8b3d-4168-995a-a4f34b320a55","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=ef23f99c88724b6a8cf448f37107c538","created_at":"2026-06-27T03:06:55.924Z","updated_at":"2026-06-27T03:06:55.924Z","phase":"Phase 1","brief_title":"Phase I clinical trial of TQB3909 tablets in subjects with advanced malignant tumors","source_id_and_acronym":"CTR20211667","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQB3909"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 02/18/2022","start_date":" 02/18/2022","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"b0fc95f1-e8d4-4ce0-b954-ab9277d58cc0","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=63aac6e991384688923e3c25abfd1747","created_at":"2026-06-27T02:50:11.981Z","updated_at":"2026-06-27T02:50:11.981Z","phase":"Phase 3","brief_title":"A Phase III clinical trial of HEC73543 tablets for the treatment of relapsed/refractory AML patients with FLT3-ITD mutations.","source_id_and_acronym":"CTR20222667","lead_sponsor":"Guangdong Dongyangguang Pharmaceutical Co., Ltd.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • decitabine • idarubicin hydrochloride • fludarabine IV • clifutinib (HEC73543)"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"5dc7d30b-675d-47cf-b2d7-ee54b5a25243","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=63c6cd147464466b828bdecde319db62","created_at":"2026-06-27T03:28:19.537Z","updated_at":"2026-06-27T03:28:19.537Z","phase":"Phase 3","brief_title":"Phase III study of SKLB1028 capsules in patients with relapsed/refractory AML with FLT3 mutations.","source_id_and_acronym":"CTR20202269","lead_sponsor":"Shijiazhuang Zhongqi Pharmaceutical Technology Co., Ltd. / Sichuan University","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • fludarabine IV • Synribo (omacetaxine mepesuccinate) • aclarubicin • ruserontinib (SKLB-1028)"],"overall_status":"Recruiting","enrollment":" Enrollment 315","initiation":"Initiation: 03/31/2021","start_date":" 03/31/2021","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"7c7a03ab-0e6c-45d3-aa86-dc6034b9fb1c","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=f16fec68b8e54c30b6c1bef0072ff7ad","created_at":"2026-06-27T03:12:27.158Z","updated_at":"2026-06-27T03:12:27.158Z","phase":"Phase 1","brief_title":"Exploratory study of IMM01 combined with azacitidine for the treatment of acute myeloid leukemia or myelodysplastic syndrome","source_id_and_acronym":"CTR20212519","lead_sponsor":"Yiming Onco Biomedical Technology (Shanghai) Co., Ltd.","biomarkers":" FLT3 • ABL1 • BCR • IDH1","pipe":" | ","alterations":" IDH2 mutation","tags":["FLT3 • ABL1 • BCR • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 01/05/2022","start_date":" 01/05/2022","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"1ab27b74-e0f4-4cec-8b70-3ecfc4fb824b","acronym":"Ven-BUCY","url":"https://clinicaltrials.gov/study/NCT07183878","created_at":"2025-09-27T08:46:54.624Z","updated_at":"2025-09-27T08:46:54.624Z","phase":"","brief_title":"Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)","source_id_and_acronym":"NCT07183878 - Ven-BUCY","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 08/20/2025","start_date":" 08/20/2025","primary_txt":" Primary completion: 08/20/2027","primary_completion_date":" 08/20/2027","study_txt":" Completion: 08/20/2028","study_completion_date":" 08/20/2028","last_update_posted":"2025-09-19"},{"id":"17c029cc-5449-4ba9-99f6-13ebaefd3227","acronym":"EVOLVE 1","url":"https://clinicaltrials.gov/study/NCT07075016","created_at":"2025-07-26T13:34:40.222Z","updated_at":"2025-07-26T13:34:40.222Z","phase":"Phase 3","brief_title":"Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy","source_id_and_acronym":"NCT07075016 - EVOLVE 1","lead_sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Tibsovo (ivosidenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 227","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-07-20"},{"id":"1788e76b-7d7b-4891-bdd0-dfbb58176132","acronym":"","url":"https://clinicaltrials.gov/study/NCT07046078","created_at":"2025-07-05T13:57:24.531Z","updated_at":"2025-07-05T13:57:24.531Z","phase":"Phase 2","brief_title":"Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer","source_id_and_acronym":"NCT07046078","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • idarubicin hydrochloride • fludarabine IV • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2025-07-02"},{"id":"2d611a75-574e-482e-91b3-3bf96d4e7ace","acronym":"CATCHAML","url":"https://clinicaltrials.gov/study/NCT04318678","created_at":"2021-01-18T20:55:40.221Z","updated_at":"2025-02-25T12:27:32.189Z","phase":"Phase 1","brief_title":"CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","source_id_and_acronym":"NCT04318678 - CATCHAML","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD123 • IL3RA","pipe":"","alterations":" ","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • mesna • CD123-CAR T cell therapy • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-24"},{"id":"8071c405-9b54-4ff6-82e5-09e8fad7fb2c","acronym":"T-LGLL","url":"https://clinicaltrials.gov/study/NCT05141682","created_at":"2021-12-02T18:54:30.785Z","updated_at":"2025-02-25T12:38:03.521Z","phase":"Phase 1/2","brief_title":"Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia","source_id_and_acronym":"NCT05141682 - T-LGLL","lead_sponsor":"Jonathan Brammer","biomarkers":" CD8","pipe":" | ","alterations":" STAT3 mutation","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STAT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Onureg (azacitidine oral)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/29/2022","start_date":" 06/29/2022","primary_txt":" Primary completion: 08/15/2024","primary_completion_date":" 08/15/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"ef9f9bd0-273f-42be-ab92-31c003721bbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01861106","created_at":"2021-01-18T08:19:16.098Z","updated_at":"2025-02-25T12:26:02.331Z","phase":"Phase 2","brief_title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","source_id_and_acronym":"NCT01861106","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GATA2","pipe":" | ","alterations":" GATA2 mutation","tags":["GATA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GATA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 144","initiation":"Initiation: 07/24/2013","start_date":" 07/24/2013","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-24"},{"id":"23ac8e6c-a9b5-4a23-995c-206f44787ba3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02890329","created_at":"2021-01-18T14:11:09.765Z","updated_at":"2025-02-25T13:48:17.623Z","phase":"Phase 1","brief_title":"Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","source_id_and_acronym":"NCT02890329","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" High ALC","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e High ALC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • azacitidine • decitabine • CS1002 (ipilimumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/05/2017","start_date":" 09/05/2017","primary_txt":" Primary completion: 10/24/2022","primary_completion_date":" 10/24/2022","study_txt":" Completion: 08/19/2025","study_completion_date":" 08/19/2025","last_update_posted":"2025-02-21"},{"id":"30691860-7f81-43a1-b334-a75b53b70fce","acronym":"","url":"https://clinicaltrials.gov/study/NCT04959175","created_at":"2021-07-13T12:53:21.217Z","updated_at":"2025-02-25T13:40:32.157Z","phase":"Phase 1/2","brief_title":"Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies","source_id_and_acronym":"NCT04959175","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • IGH","pipe":"","alterations":" ","tags":["EGFR • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 09/23/2021","start_date":" 09/23/2021","primary_txt":" Primary completion: 04/27/2027","primary_completion_date":" 04/27/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2025-02-21"},{"id":"7db8cbc0-f928-4935-a5eb-7dd8dd21f64b","acronym":"EA2192","url":"https://clinicaltrials.gov/study/NCT04858334","created_at":"2021-04-26T13:52:59.130Z","updated_at":"2025-02-25T13:40:27.622Z","phase":"Phase 2","brief_title":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation","source_id_and_acronym":"NCT04858334 - EA2192","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" PALB2 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-21"},{"id":"9dace7a4-0aa6-4f4b-ad55-e52edc08eadf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04251078","created_at":"2021-01-18T20:39:29.313Z","updated_at":"2025-02-25T13:40:03.793Z","phase":"","brief_title":"Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples","source_id_and_acronym":"NCT04251078","lead_sponsor":"Josep Carreras Leukaemia Research Institute","biomarkers":" BRAF • SF3B1 • GATA1","pipe":"","alterations":" ","tags":["BRAF • SF3B1 • GATA1"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-21"},{"id":"b8897926-0522-4fee-9673-a3eb75b62670","acronym":"","url":"https://clinicaltrials.gov/study/NCT03173937","created_at":"2021-01-18T15:38:57.471Z","updated_at":"2025-02-25T13:39:29.284Z","phase":"Phase 1/2","brief_title":"Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome","source_id_and_acronym":"NCT03173937","lead_sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","biomarkers":" CD34 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["CD34 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Omisirge (omidubicel)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 04/28/2025","primary_completion_date":" 04/28/2025","study_txt":" Completion: 03/01/2028","study_completion_date":" 03/01/2028","last_update_posted":"2025-02-21"},{"id":"611d069e-ba56-4015-ba56-94bebd608133","acronym":"","url":"https://clinicaltrials.gov/study/NCT03839446","created_at":"2021-01-18T18:57:17.044Z","updated_at":"2025-02-25T13:52:47.649Z","phase":"Phase 2","brief_title":"Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy","source_id_and_acronym":"NCT03839446","lead_sponsor":"Robert Redner, MD","biomarkers":" CD33","pipe":" | ","alterations":" CD33 expression","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e etoposide IV • Mylotarg (gemtuzumab ozogamicin) • mitoxantrone"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 02/28/2019","start_date":" 02/28/2019","primary_txt":" Primary completion: 02/02/2023","primary_completion_date":" 02/02/2023","study_txt":" Completion: 12/22/2024","study_completion_date":" 12/22/2024","last_update_posted":"2025-02-20"},{"id":"a2748e44-3f76-4ef4-9c24-1b7476039a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554393","created_at":"2022-09-26T14:56:10.693Z","updated_at":"2025-02-25T13:49:33.606Z","phase":"Phase 2","brief_title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","source_id_and_acronym":"NCT05554393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation","tags":["TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 09/13/2024","start_date":" 09/13/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"afc34dd5-440d-4768-b2d3-1f68bbdafbb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05470491","created_at":"2022-07-22T11:56:13.684Z","updated_at":"2025-02-25T13:54:33.177Z","phase":"Phase 1/2","brief_title":"Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...","source_id_and_acronym":"NCT05470491","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • Selzentry (maraviroc) • plerixafor"],"overall_status":"Recruiting","enrollment":" Enrollment 265","initiation":"Initiation: 01/26/2023","start_date":" 01/26/2023","primary_txt":" Primary completion: 07/30/2026","primary_completion_date":" 07/30/2026","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2025-02-20"},{"id":"b813594c-e262-462c-9ebd-af975b8871b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04375631","created_at":"2021-01-18T21:08:17.296Z","updated_at":"2025-02-25T13:53:16.560Z","phase":"Phase 1","brief_title":"CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia","source_id_and_acronym":"NCT04375631","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/03/2020","start_date":" 12/03/2020","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 03/17/2027","study_completion_date":" 03/17/2027","last_update_posted":"2025-02-20"}]